公开(公告)号：WO2017033123A1

公开(公告)日：2017-03-02

申请号：PCT/IB2016/055016

申请日：2016-08-22

Applicant: AGRAWAL, Babita ,  KUMAR, Rakesh ,  GUPTA, Nancy

Inventor： AGRAWAL, Babita ,  KUMAR, Rakesh ,  GUPTA, Nancy

IPC: A61K39/02 ,  A61K39/00 ,  A61P29/00 ,  A61P3/00 ,  A61P31/04 ,  A61P37/02 ,  A61P37/04

CPC classification number: A61K35/74

Abstract: The present disclosure provides immunomodulatory compositions comprising live Caulobacter crescentus (CC). Immunomodulatory compositions of the present disclosure are useful for modulating an immune response in an individual. The present disclosure thus provides methods of modulating an immune response in an individual, involving administering an immunomodulatory composition comprising live CC to the individual.

Abstract translation: 本公开提供包含活细弧新月牙（CC）的免疫调节组合物。 本公开的免疫调节组合物可用于调节个体的免疫应答。 本公开因此提供了调节个体的免疫应答的方法，包括向个体施用包含活CC的免疫调节组合物。

公开(公告)号：WO2013009606A1

公开(公告)日：2013-01-17

申请号：PCT/US2012/045728

申请日：2012-07-06

Applicant: SPECIALTY COATING SYSTEMS, INC. ,  KUMAR, Rakesh ,  KE, Yingfei ,  ENGLAND, Dustin

Inventor： KUMAR, Rakesh ,  KE, Yingfei ,  ENGLAND, Dustin

IPC: A61L27/34 ,  A61L27/54 ,  A61L29/08 ,  A61L29/16 ,  A61L31/10 ,  A61L31/16

CPC classification number: A61L27/54 ,  A61L27/34 ,  A61L29/085 ,  A61L29/16 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/202 ,  A61L2300/404 ,  A61L2300/80 ,  C08L65/04

Abstract: Antimicrobial parylene coatings and methods for their vapor-phase deposition.

Abstract translation: 抗微生物聚对二甲苯涂层及其气相沉积方法。

公开(公告)号：WO2012106302A1

公开(公告)日：2012-08-09

申请号：PCT/US2012/023261

申请日：2012-01-31

Applicant: GLAXO WELLCOME MANUFACTURING PTE LTD ,  SUNNYBROOK RESEARCH INSTITUTE ,  KUMAR, Rakesh ,  KERBEL, Robert S.

Inventor： KUMAR, Rakesh ,  KERBEL, Robert S.

IPC: A61K31/416 ,  A61K31/47 ,  C07D231/56

CPC classification number: A61K31/506 ,  A61K31/4745 ,  A61K45/06 ,  C07D231/56 ,  A61K2300/00

Abstract: The present invention relates to a method of treating breast cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a breast cancer treatment method that includes administering 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, or a pharmaceutically acceptable salt thereof, and (S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7] indolizino [1,2-b]quinoline-3,14-(4H,12H)-dione, or a pharmaceutically acceptable salt thereof, to a human in need thereof.

Abstract translation: 本发明涉及治疗人类乳腺癌的方法和用于治疗的药物组合物。 特别地，该方法涉及一种乳腺癌治疗方法，其包括施用5 - [[4 - [（2,3-二甲基-2H-吲唑-6-基）甲基氨基] -2-嘧啶基]氨基] -2-甲基苯磺酰胺 ，或其药学上可接受的盐，和（S）-10 - [（二甲基氨基）甲基] -4-乙基-4,9-二羟基-1H-吡喃并[3'，4'：6,7]吲哚并[ 2-b]喹啉-3,14-（4H，12H） - 二酮或其药学上可接受的盐。

公开(公告)号：WO2012097021A1

公开(公告)日：2012-07-19

申请号：PCT/US2012/020863

申请日：2012-01-11

Applicant: GLAXOSMITHKLINE LLC ,  KUMAR, Rakesh

Inventor： KUMAR, Rakesh

IPC: A01N43/56

CPC classification number: A61K38/05 ,  A61K9/0019 ,  A61K31/4155 ,  A61K31/69 ,  A61K38/005 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering a proteasome inhibiting compound, and /\/-{(1 S )-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1 - methyl-1 H -pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, and optional additional antineoplastic agents, to a human in need thereof.

Abstract translation: 本发明涉及一种治疗人类癌症的方法和用于治疗的药物组合物。 特别地，该方法涉及一种癌症治疗方法，其包括施用蛋白酶体抑制化合物和/或 - （（1S）-2-氨基-1 - [（3-氟苯基）甲基]乙基} -5-氯 - 4-（4-氯-1-甲基-1H-吡唑-5-基）-2-噻吩甲酰胺或其药学上可接受的盐和任选的另外的抗肿瘤药物。

公开(公告)号：WO2012089647A1

公开(公告)日：2012-07-05

申请号：PCT/EP2011/073911

申请日：2011-12-23

Applicant: SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. ,  KUMAR, Rakesh ,  SAID, Michael George

Inventor： KUMAR, Rakesh ,  SAID, Michael George

IPC: F16L59/14 ,  F16L59/15 ,  F17D1/00 ,  F17D1/08

CPC classification number: F16L1/12 ,  B65G5/00 ,  F16L11/127 ,  F16L59/141 ,  F16L59/15

Abstract: The present invention relates to a cryogenic fluid transfer tunnel (10) that can be used as a liquefied natural gas (LNG) transfer tunnel. A lining jacket (20) is provided, wherein a cryogenic fluid carrier line (30) and one or more voids (50) comprising cryogenic insulating material (60) are located. A method of installing such a tunnel and a method of cooling a cryogenic fluid carrier line in such a tunnel is also described.

Abstract translation: 本发明涉及可用作液化天然气（LNG）输送隧道的低温流体输送隧道（10）。 提供衬套（20），其中定位有低温流体载体管线（30）和包括低温绝缘材料（60）的一个或多个空隙（50）。 还描述了在这种隧道中安装这种隧道的方法和冷却低温流体载体线的方法。

公开(公告)号：WO2012036919A3

公开(公告)日：2012-03-22

申请号：PCT/US2011/050302

申请日：2011-09-02

Applicant: GLAXOSMITHKLINE LLC ,  KUMAR, Rakesh

Inventor： KUMAR, Rakesh

IPC: A01N41/06 ,  A61K31/18

Abstract: A novel combination comprising the VEGFR inhibitor 5-[[4-[(2,3-dimethyl-2H- indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, or a pharmaceutically acceptable salt thereof, with a B-Raf inhibitor, particularly N-{3-[5- (2-Amino-4-pyrimidinyl)-2-(1,1 -dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6- difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of VEGFR and/or B-Raf is beneficial.

公开(公告)号：WO2012036919A2

公开(公告)日：2012-03-22

申请号：PCT/US2011050302

申请日：2011-09-02

Applicant: GLAXOSMITHKLINE LLC ,  KUMAR RAKESH

Inventor： KUMAR RAKESH

IPC: A61K31/506

CPC classification number: A61K31/506 ,  A61K9/0019 ,  A61K9/10 ,  A61K9/4858 ,  A61K31/185 ,  A61K2300/00

Abstract: A novel combination comprising the VEGFR inhibitor 5-[[4-[(2,3-dimethyl-2H- indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, or a pharmaceutically acceptable salt thereof, with a B-Raf inhibitor, particularly N-{3-[5- (2-Amino-4-pyrimidinyl)-2-(1,1 -dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6- difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of VEGFR and/or B-Raf is beneficial.

Abstract translation: 包含VEGFR抑制剂5 - [[4 - [（2,3-二甲基-2H-吲唑-6-基）甲基氨基] -2-嘧啶基]氨基] -2-甲基苯磺酰胺或其药学上可接受的盐的新型组合， 与B-Raf抑制剂，特别是N- {3- [5-（2-氨基-4-嘧啶基）-2-（1,1-二甲基乙基）-1,3-噻唑-4-基] -2-氟苯基 } -2,6-二氟苯磺酰胺或其药学上可接受的盐，包含其的药物组合物以及在治疗其中抑制VEGFR和/或B-Raf有益的条件下使用这些组合和组合物的方法。

公开(公告)号：WO2011037534A1

公开(公告)日：2011-03-31

申请号：PCT/SG2009/000355

申请日：2009-09-25

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH ,  SEIKO INSTRUMENTS INC. ,  PREMACHANDRAN, Chirayarikathu Veedu Sankarapillai ,  KUMAR, Rakesh ,  RANGANATHAN, Nagarajan ,  CHOI, Won Kyoung ,  LIAO, Ebin ,  MITSUOKA, Yasuyuki ,  TAKAHASHI, Hiroshi ,  MITSUSUE, Ryuta

Inventor： PREMACHANDRAN, Chirayarikathu Veedu Sankarapillai ,  KUMAR, Rakesh ,  RANGANATHAN, Nagarajan ,  CHOI, Won Kyoung ,  LIAO, Ebin ,  MITSUOKA, Yasuyuki ,  TAKAHASHI, Hiroshi ,  MITSUSUE, Ryuta

IPC: B81B7/02 ,  H01L21/44 ,  H01L23/48

CPC classification number: H01L21/6836 ,  B81B2207/092 ,  B81B2207/093 ,  B81B2207/097 ,  B81C2203/019 ,  H01L24/48 ,  H01L24/94 ,  H01L2224/48091 ,  H01L2224/48227 ,  H01L2224/48465 ,  H01L2924/00014 ,  H01L2924/01012 ,  H01L2924/01013 ,  H01L2924/01029 ,  H01L2924/01077 ,  H01L2924/01078 ,  H01L2924/01079 ,  H01L2924/01322 ,  H01L2924/01327 ,  H01L2924/09701 ,  H01L2924/10253 ,  H01L2924/1461 ,  H01L2924/16195 ,  H01L2924/16235 ,  H01L2924/16315 ,  H01L2924/19041 ,  H01L2924/19107 ,  H01L2924/3011 ,  H01L2924/00 ,  H01L2224/45099 ,  H01L2224/45015 ,  H01L2924/207

Abstract: In an embodiment, a wafer level package may be provided. The wafer level package may include a device wafer including a MEMS device, a cap wafer disposed over the device wafer, at least one first interconnect disposed between the device wafer and the cap wafer and configured to provide an electrical connection between the device wafer and the cap wafer, and a conformal sealing ring disposed between the device wafer and the cap wafer and configured to surround the at least one first interconnect and the MEMS device so as to provide a conformally sealed environment for the at least one first interconnect and the MEMS device, wherein the conformal sealing ring may be configured to conform to a respective suitable surface of the device wafer and the cap wafer when the device wafer may be bonded to the cap wafer. A method of forming a wafer level package may also be provided.

Abstract translation: 在一个实施例中，可以提供晶片级封装。 晶片级封装可以包括包括MEMS器件的器件晶片，设置在器件晶片上的帽晶片，设置在器件晶片和帽晶片之间的至少一个第一互连，并且被配置为在器件晶片和晶片级封装之间提供电连接 帽状晶片和保形密封环，其设置在器件晶片和盖晶片之间并且被配置为围绕至少一个第一互连和MEMS器件，以便为至少一个第一互连和MEMS器件提供保形密封的环境 ，其中所述保形密封环可以被配置为当所述器件晶片可以结合到所述盖晶片时，使其符合所述器件晶片和所述盖晶片的相应合适的表面。 还可以提供一种形成晶片级封装的方法。

公开(公告)号：WO2010097811A1

公开(公告)日：2010-09-02

申请号：PCT/IN2010/000110

申请日：2010-02-25

Applicant: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH ,  SINHA, Arun, Kumar ,  SHARMA, Abhishek ,  KUMAR, Rakesh ,  SHARMA, Naina

Inventor： SINHA, Arun, Kumar ,  SHARMA, Abhishek ,  KUMAR, Rakesh ,  SHARMA, Naina

IPC: C07C45/30 ,  C07C311/49 ,  C07D317/54 ,  C07C47/228 ,  C07C47/23 ,  C07C47/24 ,  C07C47/277

CPC classification number: C07C45/28 ,  C07C45/30 ,  C07C249/16 ,  C07C311/49 ,  C07D317/54 ,  C07C47/228 ,  C07C47/24 ,  C07C47/23 ,  C07C47/277

Abstract: The present invention provides a process for the preparation of some novel 2-aryl and 2,2-diaryl aldehydes and analogues which are privileged intermediates for commercially important nonsteroidal anti-inflammatory drugs including naproxen, flurbiprofen and potent anticancer drug candidates, including phenstatin through a unique single step synthetic methodology utilizing easily available substrates in the form of aryl alkenes as well as environmentally benign aqueous reaction conditions in the form of solvents such as mixtures of water and DMSO or Dioxane and reagents N-bromosuccinimide, N- iodosuccinimide, N-cholorosuccinimide and phase transfer catalyst such as cetyltrimethyl ammonium bromide, N-hexyl ammonium chloride for a reaction time varying from 1min- 30min, depending upon microwave or conventional heating, without using expensive transition metal catalysts or lewis acids/bases with yield varying from 35-55 %, depending upon the solvent and substrate used. The developed method provides a clean and convenient alternative to access a diverse range of medicinally important 2-aryl and 2,2- diaryl aldehyde based scaffolds in lieu of the conventional multistep protocols employing expensive and hazardous transition metal catalysts and lewis acids/bases.

Abstract translation: 本发明提供了制备一些新的2-芳基和2,2-二芳基醛和类似物的方法，它们是商业上重要的非甾体抗炎药物的特权中间体，包括萘普生，氟比洛芬和有效的抗癌药物候选物，包括通过 利用芳基烯烃形式的容易获得的底物以及以水和DMSO或二恶烷的混合物和二恶烷的溶剂形式的环境友好的水性反应条件的独特的单步合成方法和试剂N-溴代琥珀酰亚胺，N-碘代琥珀酰亚胺，N-氯代琥珀酰亚胺 和相转移催化剂如十六烷基三甲基溴化铵，N-己基氯化铵，反应时间根据微波或常规加热反应时间为1min-30min，而不使用昂贵的过渡金属催化剂或路易斯酸/碱，产率从35-55 取决于所用的溶剂和底物。 开发的方法提供了一种干净和方便的替代方案，用于获得各种各样的药物重要的2-芳基和2,2-二芳基醛基支架，代替采用昂贵且危险的过渡金属催化剂和路易斯酸/碱的常规多步骤方案。

公开(公告)号：WO2009113961A1

公开(公告)日：2009-09-17

申请号：PCT/SG2008/000077

申请日：2008-03-11

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH ,  KUMAR, RAKESH ,  SUBRAMANIAM, BALAKUMER ,  RANGANATHAN, NAGARAJAN ,  LI, HONG YU

Inventor： KUMAR, RAKESH ,  SUBRAMANIAM, BALAKUMER ,  RANGANATHAN, NAGARAJAN ,  LI, HONG YU

IPC: H01L27/00 ,  H01L31/00

CPC classification number: G02B6/122 ,  G02B6/12004 ,  G02B6/136 ,  G02B6/30 ,  H01L27/1203

Abstract: A method for reducing optical coupling loss in a dielectric stack, a dielectric stack, and an optical device. The method comprises the steps of removing at least a portion of the dielectric stack associated with one or more metal layers of the dielectric stack in a region where optical losses are to be eliminated; and replacing said portion with a homogenous dielectric material.

Abstract translation: 一种用于减小电介质堆叠，电介质堆叠和光学装置中的光耦合损耗的方法。 该方法包括以下步骤：在要消除光损耗的区域中去除与电介质叠层的一个或多个金属层相关联的电介质叠层的至少一部分; 并用均匀的电介质材料代替所述部分。